Polivy
NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma
February 26, 2020Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche
It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …
EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma
January 21, 2020Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma
The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.
Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma
June 11, 2019Manufacturing and Production, Sales and Marketing Polivy, Roche, lymphoma, pharma
Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
